{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:14:14Z","timestamp":1791472454546,"version":"4.3.4"},"reference-count":121,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Donaldson Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Irritable bowel syndrome (IBS) is a highly prevalent and debilitating disorder of gut\u2013brain interaction (DGBI) affecting millions globally. It imposes a significant burden on healthcare systems and is a leading cause of workplace absenteeism. IBS is classified into several subtypes based on predominant presenting symptoms, including IBS with constipation (IBS-C) and IBS with diarrhea (IBS-D), with each requiring targeted approaches to treatment. Some treatments, such as psychotherapy, dietary intervention, and medications like tricyclic antidepressants, are nonspecific and recommended for managing IBS symptoms across all subtypes. In contrast, therapies like secretagogues for IBS-C and eluxadoline or rifaximin for IBS-D are subtype-specific. However, many IBS treatments carry conditional recommendations and are based on low-certainty evidence, emphasizing the need for further research to expand the available treatment options. This review compares the latest IBS management guidelines from the American Gastroenterological Association (AGA), American College of Gastroenterology (ACG), British Society of Gastroenterology (BSG), and European Society for Neurogastroenterology and Motility (ESNM). Pharmacologic and non-pharmacologic therapies, including established and emerging interventions, will be explored to provide a comprehensive guide to management.<\/jats:p>","DOI":"10.3390\/jcm13226948","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T10:44:37Z","timestamp":1732013077000},"page":"6948","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7015-3075","authenticated-orcid":false,"given":"Anthony J.","family":"Papale","sequence":"first","affiliation":[{"name":"Department of Medicine, North Shore University Hospital\/Zucker School of Medicine at Hofstra University, Manhasset, NY 11030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3138-9496","authenticated-orcid":false,"given":"Robert","family":"Flattau","sequence":"additional","affiliation":[{"name":"Zucker School of Medicine at Hofstra University, Hempstead, NY 11549, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6795-1283","authenticated-orcid":false,"given":"Nandan","family":"Vithlani","sequence":"additional","affiliation":[{"name":"Zucker School of Medicine at Hofstra University, Hempstead, NY 11549, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Department of Medicine, North Shore University Hospital\/Zucker School of Medicine at Hofstra University, Manhasset, NY 11030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Nadella","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Northwell Health, New Hyde Park, NY 11040, USA"},{"name":"Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"ref_1","first-page":"203","article-title":"The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems","volume":"28","author":"Carabotti","year":"2015","journal-title":"Ann. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10620-020-06109-5","article-title":"Microbiome and Its Role in Irritable Bowel Syndrome","volume":"65","author":"Pimentel","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11894-011-0195-7","article-title":"Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome","volume":"13","author":"Barbara","year":"2011","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_4","unstructured":"Patel, N., and Shackelford, K.B. (2024, October 02). Irritable Bowel Syndrome, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534810\/."},{"key":"ref_5","unstructured":"(2024, October 02). Rome IV Criteria\u2014Rome Foundation. Available online: https:\/\/theromefoundation.org\/rome-iv\/rome-iv-criteria\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ajg.2012.131","article-title":"Effect of gender on prevalence of irritable bowel syndrome in the community: Systematic review and meta-analysis","volume":"107","author":"Lovell","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.2015.0954","article-title":"Irritable bowel syndrome: A clinical review","volume":"313","author":"Chey","year":"2015","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00365521.2022.2028005","article-title":"The changes in prevalence and risk of irritable bowel syndrome over time in a population-based cohort, the HUNT study, Norway","volume":"57","author":"Johansen","year":"2022","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1017\/S0033291716001987","article-title":"A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset","volume":"46","author":"Sibelli","year":"2016","journal-title":"Psychol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1574887118666230508154027","article-title":"The Burden of Irritable Bowel Syndrome in Medical and Nurse Italian University Student Population: The VANVITELLI-IBS Survey","volume":"18","author":"Gravina","year":"2023","journal-title":"Rev. Recent Clin. Trials."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MCG.0000000000000114","article-title":"Predictive factors for the diagnosis of irritable bowel syndrome in a large cohort of 440,822 young adults","volume":"49","author":"Carter","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Grover, M., Kolla, B.P., Pamarthy, R., Mansukhani, M.P., Breen-Lyles, M., He, J.-P., and Merikangas, K.R. (2021). Psychological, physical, and sleep comorbidities and functional impairment in irritable bowel syndrome: Results from a national survey of U.S. adults. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0245323"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S2468-1253(20)30217-X","article-title":"Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis","volume":"5","author":"Oka","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.gastro.2008.12.015","article-title":"Burden of digestive diseases in the United States part I: Overall and upper gastrointestinal diseases","volume":"136","author":"Everhart","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1053\/gast.2002.32978","article-title":"The burden of selected digestive diseases in the United States","volume":"122","author":"Sandler","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"936960","DOI":"10.1155\/2012\/936960","article-title":"Benefits from long-term treatment in irritable bowel syndrome","volume":"2012","author":"Evangelista","year":"2012","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.cgh.2019.08.016","article-title":"Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results from the IBS in America Survey","volume":"17","author":"Ballou","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e13762","DOI":"10.1111\/nmo.13762","article-title":"European society of neurogastroenterology and motility guidelines on functional constipation in adults","volume":"32","author":"Serra","year":"2020","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ueg2.12259","article-title":"Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility","volume":"10","author":"Savarino","year":"2022","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","article-title":"British Society of Gastroenterology guidelines on the management of irritable bowel syndrome","volume":"70","author":"Vasant","year":"2021","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.3748\/wjg.v20.i22.6759","article-title":"Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine","volume":"20","author":"Saha","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1055\/s-2008-1038600","article-title":"The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: A randomised controlled trial","volume":"29","author":"Daley","year":"2008","journal-title":"Int. J. Sports Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Riezzo, G., Prospero, L., D\u2019attoma, B., Ignazzi, A., Bianco, A., Franco, I., Curci, R., Campanella, A., Bonfiglio, C., and Osella, A.R. (2023). The Impact of a Twelve-Week Moderate Aerobic Exercise Program on Gastrointestinal Symptom Profile and Psychological Well-Being of Irritable Bowel Syndrome Patients: Preliminary Data from a Southern Italy Cohort. J. Clin. Med., 12.","DOI":"10.3390\/jcm12165359"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/ajg.2010.480","article-title":"Physical activity improves symptoms in irritable bowel syndrome: A randomized controlled trial","volume":"106","author":"Johannesson","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e13461","DOI":"10.1111\/nmo.13461","article-title":"Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials","volume":"31","author":"Zhou","year":"2019","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_27","first-page":"CD011497","article-title":"Physical activity for treatment of irritable bowel syndrome","volume":"6","author":"Nunan","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.3748\/wjg.v29.i41.5668","article-title":"Inflammatory bowel diseases patients suffer from significant low levels and barriers to physical activity: The \u201cBE-FIT-IBD\u201d study","volume":"29","author":"Gravina","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.cgh.2021.07.006","article-title":"AGA Clinical Practice Update on Management of Chronic Gastrointestinal Pain in Disorders of Gut-Brain Interaction: Expert Review","volume":"19","author":"Keefer","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/ajg.2014.148","article-title":"Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: Systematic review and meta-analysis","volume":"109","author":"Ford","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gutjnl-2020-321191","article-title":"Efficacy of psychological therapies for irritable bowel syndrome: Systematic review and network meta-analysis","volume":"69","author":"Black","year":"2020","journal-title":"Gut"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1037\/0022-006X.72.6.1100","article-title":"Psychological treatments for irritable bowel syndrome: A systematic review and meta-analysis","volume":"72","author":"Lackner","year":"2004","journal-title":"J. Consult. Clin. Psychol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1053\/j.gastro.2024.05.010","article-title":"Effect of Brain-Gut Behavioral Treatments on Abdominal Pain in Irritable Bowel Syndrome: Systematic Review and Network Meta-Analysis","volume":"167","author":"Goodoory","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1053\/j.gastro.2018.01.045","article-title":"Best Practice Update: Incorporating Psychogastroenterology into Management of Digestive Disorders","volume":"154","author":"Keefer","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.gastro.2018.03.063","article-title":"Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome","volume":"155","author":"Lackner","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e35260","DOI":"10.2196\/35260","article-title":"Internet-Delivered Cognitive Behavioral Therapy in Patients With Irritable Bowel Syndrome: Systematic Review and Meta-Analysis","volume":"24","author":"Kim","year":"2022","journal-title":"J. Med. Internet Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/apt.13202","article-title":"Review article: Gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease","volume":"41","author":"Peters","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(18)30310-8","article-title":"Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): A multicentre randomised controlled trial","volume":"4","author":"Flik","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/ajg.2011.340","article-title":"Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials","volume":"107","author":"Lindfors","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/00029157.2022.2051424","article-title":"Hypnotherapy for persons with irritable bowel syndrome: A three-arm randomized controlled trial","volume":"65","author":"Wan","year":"2022","journal-title":"Am. J. Clin. Hypn."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3109\/00365521.2012.733955","article-title":"Effects on gastrointestinal transit and antroduodenojejunal manometry after gut-directed hypnotherapy in irritable bowel syndrome (IBS)","volume":"47","author":"Lindfors","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ajg.2013.105","article-title":"Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life","volume":"108","author":"Bengtsson","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/ajg.2014.195","article-title":"The effect of fiber supplementation on irritable bowel syndrome: A systematic review and meta-analysis","volume":"109","author":"Moayyedi","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"b3154","DOI":"10.1136\/bmj.b3154","article-title":"Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial","volume":"339","author":"Bijkerk","year":"2009","journal-title":"BMJ"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/MEG.0000000000000425","article-title":"The role of fiber supplementation in the treatment of irritable bowel syndrome: A systematic review and meta-analysis","volume":"27","author":"Nagarajan","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1053\/j.gastro.2021.12.248","article-title":"AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review","volume":"162","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.gastro.2022.04.016","article-title":"AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome with Constipation","volume":"163","author":"Chang","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.gastro.2020.06.099","article-title":"Behavioral and Diet Therapies in Integrated Care for Patients with Irritable Bowel Syndrome","volume":"160","author":"Chey","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Varj\u00fa, P., Farkas, N., Hegyi, P., Garami, A., Szab\u00f3, I., Ill\u00e9s, A., Solym\u00e1r, M., Vincze, \u00c1., Balask\u00f3, M., and P\u00e1r, G. (2017). Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet improves symptoms in adults suffering from irritable bowel syndrome (IBS) compared to standard IBS diet: A meta-analysis of clinical studies. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182942"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/gutjnl-2017-313750","article-title":"The low FODMAP diet: Recent advances in understanding its mechanisms and efficacy in IBS","volume":"66","author":"Staudacher","year":"2017","journal-title":"Gut"},{"key":"ref_51","first-page":"17","article-title":"Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics)","volume":"18","author":"Khalif","year":"2009","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41395-018-0195-4","article-title":"A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome","volume":"113","author":"Dionne","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_53","first-page":"488","article-title":"Behandlung des Colon irritabile. Wirksamkeit und Vertr\u00e4glichkeit von Buscopan plus, Buscopan, Paracetamol und Plazebo bei ambulanten Patienten mit Colon irritabile [The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon]","volume":"108","author":"Ewe","year":"1990","journal-title":"Fortschr. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00004836-198106000-00009","article-title":"Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride)","volume":"3","author":"Page","year":"1981","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1742-1241.1967.tb07119.x","article-title":"An assessment of dicyclomine hydrochloride (\u2018Merbentyl\u2019) in the irritable colon syndrome","volume":"21","author":"Matts","year":"1967","journal-title":"Br. J. Clin. Pract."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/apt.14519","article-title":"Review article: The physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders","volume":"47","author":"Chumpitazi","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2019.08.026","article-title":"Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients with Irritable Bowel Syndrome","volume":"158","author":"Weerts","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s10620-015-3858-7","article-title":"A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms","volume":"61","author":"Cash","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.14309\/ajg.0000000000001395","article-title":"Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial","volume":"116","author":"Nee","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Alammar, N., Wang, L., Saberi, B., Nanavati, J., Holtmann, G., Shinohara, R.T., and Mullin, G.E. (2019). The impact of peppermint oil on the irritable bowel syndrome: A meta-analysis of the pooled clinical data. BMC Complement. Altern. Med., 19.","DOI":"10.1186\/s12906-018-2409-0"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41395-018-0222-5","article-title":"Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis","volume":"114","author":"Ford","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2017.11.279","article-title":"Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report","volume":"154","author":"Drossman","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2036.1994.tb00273.x","article-title":"Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome","volume":"8","author":"Gorard","year":"1994","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s10620-007-9830-4","article-title":"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial","volume":"53","author":"Talley","year":"2008","journal-title":"Dig. Dis. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1176\/appi.psy.50.1.78","article-title":"A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome","volume":"50","author":"Masand","year":"2009","journal-title":"Psychosomatics"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1542-3565(03)70039-1","article-title":"The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double blind, randomized, placebo-controlled study","volume":"1","author":"Kuiken","year":"2003","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1136\/gut.2005.077503","article-title":"A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome","volume":"55","author":"Tack","year":"2006","journal-title":"Gut"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41395-018-0084-x","article-title":"American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome","volume":"113","author":"Ford","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG Clinical Guideline: Management of Irritable Bowel Syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1463-1318.2009.01990.x","article-title":"A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome","volume":"12","author":"Awad","year":"2010","journal-title":"Color. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/j.gastro.2022.04.017","article-title":"AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome with Diarrhea","volume":"163","author":"Lembo","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ajg.2013.197","article-title":"Randomized clinical trial: Macrogol\/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome","volume":"108","author":"Chapman","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/CIA.S2938","article-title":"Lubiprostone: A novel treatment for chronic constipation","volume":"3","author":"Lacy","year":"2008","journal-title":"Clin. Interv. Aging"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome\u2014Results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1007\/s10620-017-4680-1","article-title":"Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders","volume":"62","author":"Cryer","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.mayocp.2016.01.015","article-title":"Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"91","author":"Li","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_77","first-page":"7","article-title":"The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation","volume":"135","author":"Lang","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1756284818777945","DOI":"10.1177\/1756284818777945","article-title":"Plecanatide: A new guanylate cyclase agonist for the treatment of chronic idiopathic constipation","volume":"11","author":"Rao","year":"2018","journal-title":"Therap Adv Gastroenterol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/ajg.2012.255","article-title":"A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation","volume":"107","author":"Rao","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/nmo.12292","article-title":"Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): A systematic review and meta-analysis","volume":"26","author":"Atluri","year":"2014","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/1871523018666190911121306","article-title":"Tegaserod for the Treatment of Irritable Bowel Syndrome","volume":"19","author":"Madia","year":"2020","journal-title":"Antiinflamm. Antiallergy Agents Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000001313","article-title":"Tegaserod for Irritable Bowel Syndrome with Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials","volume":"116","author":"Shah","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","article-title":"A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation","volume":"16","author":"Novick","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","article-title":"Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation","volume":"15","author":"Fumagalli","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_86","first-page":"G543","article-title":"NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons","volume":"326","author":"King","year":"2024","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/ajg.2017.41","article-title":"Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: A phase 2, randomized, placebo-controlled efficacy and safety trial","volume":"112","author":"Chey","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"281","DOI":"10.14309\/ajg.0000000000000516","article-title":"Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: A 12-week, placebo-controlled phase 3 trial (T3MPO-1)","volume":"115","author":"Chey","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.14309\/ajg.0000000000001056","article-title":"Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: A 26-week, placebo-controlled phase 3 trial (T3MPO-2)","volume":"116","author":"Chey","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_90","first-page":"145","article-title":"Mechanisms of action of loperamide","volume":"96","author":"Ooms","year":"1984","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-133-2-200007180-00013","article-title":"Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials","volume":"133","author":"Jailwala","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jcag\/gwy071","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS)","volume":"2","author":"Moayyedi","year":"2019","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e24361","DOI":"10.1097\/MD.0000000000024361","article-title":"Efficacy of opioid receptor modulators in patients with irritable bowel syndrome: A systematic review and meta-analysis","volume":"100","author":"Li","year":"2021","journal-title":"Medicine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for Irritable Bowel Syndrome with Diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.gastro.2014.09.002","article-title":"American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Chang","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/2040622317714389","article-title":"Eluxadoline in irritable bowel syndrome with diarrhea: Rationale, evidence and place in therapy","volume":"8","author":"Barshop","year":"2017","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.14309\/ajg.0000000000000327","article-title":"Efficacy and Safety of Eluxadoline in Patients with Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study","volume":"114","author":"Brenner","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1756284819897531","DOI":"10.1177\/1756284819897531","article-title":"Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: A narrative review","volume":"13","author":"Chey","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.15001","article-title":"Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome","volume":"48","author":"Ford","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ajg.2011.355","article-title":"The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis","volume":"107","author":"Menees","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","article-title":"Repeat Treatment with Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.amjmed.2011.08.026","article-title":"Evaluation of harm in the pharmacotherapy of irritable bowel syndrome","volume":"125","author":"Shah","year":"2012","journal-title":"Am. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2009.223","article-title":"Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis","volume":"104","author":"Ford","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Yu, T., Tang, Y., Xiong, W., Shen, X., Jiang, L., and Lin, L. (2017). Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172846"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1756283X13491798","article-title":"A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program","volume":"6","author":"Tong","year":"2013","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/ajg.2014.215","article-title":"Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea","volume":"109","author":"Camilleri","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.14309\/ajg.0000000000000696","article-title":"The Role of Bile Acids in Chronic Diarrhea","volume":"115","author":"Camilleri","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gutjnl-2013-305965","article-title":"Increased colonic bile acid exposure: A relevant factor for symptoms and treatment in IBS","volume":"64","author":"Bajor","year":"2015","journal-title":"Gut"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/apt.13065","article-title":"Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome","volume":"41","author":"Camilleri","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1016\/j.cgh.2020.02.027","article-title":"Effects of Colesevelam on Bowel Symptoms, Biomarkers, and Colonic Mucosal Gene Expression in Patients With Bile Acid Diarrhea in a Randomized Trial","volume":"18","author":"Vijayvargiya","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/j.gastro.2017.05.003","article-title":"Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: A pilot study in patients with irritable bowel syndrome","volume":"153","author":"Hall","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2338322","DOI":"10.1080\/19490976.2024.2338322","article-title":"A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome","volume":"16","author":"Srivastava","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S2468-1253(20)30056-X","article-title":"Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: A multicentre, randomised, double-blind, placebo-controlled clinical trial","volume":"5","author":"Andresen","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Lewis, E.D., Antony, J.M., Crowley, D.C., Piano, A., Bhardwaj, R., Tompkins, T.A., and Evans, M. (2020). Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in alleviating symptoms of irritable bowel syndrome (IBS): A randomized, placebo-controlled study. Nutrients, 12.","DOI":"10.3390\/nu12041159"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Martoni, C.J., Srivastava, S., and Leyer, G.J. (2020). Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial. Nutrients, 12.","DOI":"10.3390\/nu12020363"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Skrzyd\u0142o-Radoma\u0144ska, B., Prozorow-Kr\u00f3l, B., Cicho\u017c-Lach, H., Majsiak, E., Bier\u0142a, J.B., Kanarek, E., Sowi\u0144ska, A., and Cukrowska, B. (2021). The effectiveness and safety of multi-strain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: A randomized controlled study. Nutrients, 13.","DOI":"10.3390\/nu13030756"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.3748\/wjg.v29.i28.4451","article-title":"Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome","volume":"29","author":"Martoni","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/apt.17239","article-title":"Randomised controlled trial: Effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome","volume":"56","author":"Algera","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1016\/j.cgh.2022.02.045","article-title":"Efficacy and acceptability of dietary therapies in non-constipated irritable bowel syndrome: A randomized trial of traditional dietary advice, the low FODMAP diet, and the gluten-free diet","volume":"20","author":"Rej","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1053\/j.gastro.2013.01.049","article-title":"A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: Effects on bowel frequency and intestinal function","volume":"144","author":"Camilleri","year":"2013","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6948\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:34:37Z","timestamp":1760114077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":121,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13226948"],"URL":"https:\/\/doi.org\/10.3390\/jcm13226948","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]}}}